SURGE: Supporting UnderRepresented Minorities in Genomics-based Cancer Trial Enrollment (Intervention)
Launched by NADINE MCCLEARY, MD, MPH · May 11, 2022
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
The SURGE trial is designed to help increase the participation of underrepresented groups in clinical trials for cancer treatment. It focuses on patients with gastrointestinal, hematologic (blood), or thoracic (lung) cancers who are in need of active treatment. The goal of this study is to identify and address the challenges that prevent some patients from getting the genomic testing that is important for determining the best treatment options. To help with this, the study will provide a patient navigator to guide participants, a text message questionnaire to gather information, and an informational video to explain the process.
Eligible participants include adults aged 18 and older who identify as Black, Latinx, or are older adults aged 70 and above, and who are scheduled for a new patient consultation at specific cancer treatment centers. Participants must have a suspected or confirmed advanced cancer that needs treatment. If you choose to join the trial, you can expect support from the patient navigator and will be asked to answer questions via text to help improve the trial process. This study is currently recruiting participants, and it aims to create a more equitable environment in cancer clinical trials for everyone.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult (age 18 years or older)
- • Black, Latinx, OR older adult (age 70 years or older)
- • Scheduled for a new patient consultation
- • Suspected or confirmed advanced malignancy (requiring active treatment)
- • Gastrointestinal, hematologic, or thoracic cancer
- • DFCI patient at Longwood/Chestnut Hill, DFCI satellite at St. Elizabeth's Medical Center, or DFCI satellite at Merrimack Valley
- Exclusion Criteria:
- • Malignancy or former malignancy that requires only surveillance
- • Not continuing care at a participating DFCI site
- • Speaks a language other than English or Spanish
- • Unable to provide consent
About Nadine Mccleary, Md, Mph
Dr. Nadine McCleary, MD, MPH, is a distinguished clinical trial sponsor with a robust background in public health and medicine. With a focus on advancing medical research and improving patient outcomes, Dr. McCleary leads innovative clinical trials that aim to address critical health challenges. Her expertise encompasses the design, implementation, and oversight of trials across various therapeutic areas, ensuring adherence to regulatory standards and ethical considerations. Committed to fostering collaboration among multidisciplinary teams, she strives to translate research findings into practical solutions that enhance healthcare delivery and patient well-being.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Brighton, Massachusetts, United States
Methuen, Massachusetts, United States
Patients applied
Trial Officials
Nadine J McCleary, MD MPH
Principal Investigator
Dana-Farber Cancer Institute
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials